CI Stock Forecast 2025-2026
Distance to CI Price Targets
CI Price Momentum
10 Quality Stocks Worth Considering Now
Researching Cigna (CI) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on CI and similar high-potential opportunities.
Latest CI Stock Price Targets & Analyst Predictions
Based on our analysis of 36 Wall Street analysts, CI has a bullish consensus with a median price target of $360.00 (ranging from $323.00 to $405.00). The overall analyst rating is Strong Buy (8.6/10). Currently trading at $321.23, the median forecast implies a 12.1% upside. This outlook is supported by 19 Buy, 6 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Andrew Mok at Barclays, projecting a 26.1% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CI Analyst Ratings
CI Price Target Range
Latest CI Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CI.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 20, 2025 | Cantor Fitzgerald | Sarah James | Overweight | Maintains | $365.00 |
| Feb 4, 2025 | Wells Fargo | Stephen Baxter | Equal-Weight | Maintains | $341.00 |
| Feb 4, 2025 | Truist Securities | David Macdonald | Buy | Maintains | $375.00 |
| Feb 3, 2025 | UBS | Kevin Caliendo | Buy | Maintains | $390.00 |
| Feb 3, 2025 | Piper Sandler | Jessica Tassan | Overweight | Reiterates | $348.00 |
| Jan 31, 2025 | Morgan Stanley | Erin Wright | Overweight | Maintains | $379.00 |
| Jan 31, 2025 | Raymond James | John Ransom | Strong Buy | Reiterates | $360.00 |
| Jan 31, 2025 | Cantor Fitzgerald | Sarah James | Overweight | Maintains | $350.00 |
| Jan 31, 2025 | Oppenheimer | Michael Wiederhorn | Outperform | Maintains | $375.00 |
| Jan 31, 2025 | Barclays | Andrew Mok | Overweight | Maintains | $339.00 |
| Jan 31, 2025 | Stephens & Co. | Raj Kumar | Overweight | Maintains | $380.00 |
| Jan 6, 2025 | Truist Securities | David Macdonald | Buy | Maintains | $390.00 |
| Nov 5, 2024 | Piper Sandler | Jessica Tassan | Overweight | Reiterates | $394.00 |
| Nov 5, 2024 | Barclays | Andrew Mok | Overweight | Maintains | $420.00 |
| Nov 4, 2024 | Deutsche Bank | George Hill | Buy | Maintains | $394.00 |
| Nov 1, 2024 | Stephens & Co. | Scott Fidel | Overweight | Reiterates | $410.00 |
| Nov 1, 2024 | RBC Capital | Ben Hendrix | Outperform | Maintains | $377.00 |
| Oct 23, 2024 | Cantor Fitzgerald | Sarah James | Overweight | Reiterates | $400.00 |
| Oct 1, 2024 | Cantor Fitzgerald | Sarah James | Overweight | Reiterates | $400.00 |
| Sep 20, 2024 | Cantor Fitzgerald | Sarah James | Overweight | Reiterates | $400.00 |
The Cigna Group (CI) Competitors
The following stocks are similar to Cigna based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
The Cigna Group (CI) Financial Data
The Cigna Group has a market capitalization of $86.86B with a P/E ratio of 26.4x. The company generates $247.12B in trailing twelve-month revenue with a 1.4% profit margin.
Revenue growth is +28.4% quarter-over-quarter, while maintaining an operating margin of +3.5% and return on equity of +8.6%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
The Cigna Group (CI) Business Model
About The Cigna Group
Global health services organization providing insurance coverage.
The company generates revenue by offering a wide range of insurance products, including medical, dental, disability, life, and accident coverage to both individual clients and businesses, including multinational corporations. Its operations are grounded in managed care, aiming to provide accessible and affordable healthcare solutions while managing costs effectively.
Cigna has a diverse portfolio that spans health insurance, pharmacy benefit management, and behavioral health services. It plays a significant role in the health insurance market through innovation in healthcare solutions, integrating various health services to meet the changing demands of the healthcare landscape globally.
Company Information
Sector
Healthcare
Industry
Healthcare Plans
Employees
71,295
CEO
Mr. David Michael Cordani
Country
United States
IPO Year
1982
Website
www.cigna.comThe Cigna Group (CI) Latest News & Analysis
New Strong Sell Stocks for March 20th
7 days agoAIN, EFX, and CI were added to the Zacks Rank #5 (Strong Sell) List on March 20, 2025, indicating a negative outlook for these stocks.
AIN, EFX, and CI being on the Zacks Rank #5 list signals potential underperformance, indicating investors may want to reassess their positions in these stocks.
Cigna Group (NYSE: CI) has completed the sale of its Medicare Advantage, Supplemental Benefits, Medicare Part D, and CareAllies businesses to Health Care Service Corporation.
Cigna's sale of its Medicare-related businesses may impact its revenue streams and strategic focus, influencing stock performance and investor sentiment.
Cigna has appointed CFO Brian Evanko as COO and promoted Ann Dennison to CFO, signaling a shift in upper management within the company.
Management changes can signal shifts in strategy and operational focus, potentially impacting Cigna's performance and stock valuation, which investors need to monitor closely.
Cigna Group (NYSE: CI) will participate in the Barclays 27th Annual Global Healthcare Conference on March 12, 2025, at 2:00 PM ET, featuring CFO Brian Evanko.
Cigna's participation in the Barclays Global Healthcare Conference highlights its strategic focus and investor engagement, which could influence stock performance and market perception.
The Cigna Group announces leadership changes to accelerate the company's growth strategy
14 days agoThe Cigna Group announced leadership changes, appointing Brian Evanko as President and COO and Ann Dennison as EVP and CFO. The company reaffirmed its full-year 2025 financial outlook.
Leadership changes at The Cigna Group signal a strategic shift aimed at enhancing customer focus and growth, potentially impacting financial performance and investor confidence.
Fast Money: SIEGY, GOOGL, MCHI, CI
23 days agoCNBC's Melissa Lee and the Fast Money traders discussed the final trades of the day, providing insights into market movements and investment strategies.
Final trades indicate market sentiment and trading strategies, providing insights into potential stock movements and investment opportunities for traders and investors.
Frequently Asked Questions About CI Stock
What is The Cigna Group's (CI) stock forecast for 2025?
Based on our analysis of 36 Wall Street analysts, The Cigna Group (CI) has a median price target of $360.00. The highest price target is $405.00 and the lowest is $323.00.
Is CI stock a good investment in 2025?
According to current analyst ratings, CI has 19 Buy ratings, 6 Hold ratings, and 0 Sell ratings. The stock is currently trading at $321.23. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for CI stock?
Wall Street analysts predict CI stock could reach $360.00 in the next 12 months. This represents a 12.1% increase from the current price of $321.23. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is The Cigna Group's business model?
The company generates revenue by offering a wide range of insurance products, including medical, dental, disability, life, and accident coverage to both individual clients and businesses, including multinational corporations. Its operations are grounded in managed care, aiming to provide accessible and affordable healthcare solutions while managing costs effectively.
What is the highest forecasted price for CI The Cigna Group?
The highest price target for CI is $405.00 from Andrew Mok at Barclays, which represents a 26.1% increase from the current price of $321.23.
What is the lowest forecasted price for CI The Cigna Group?
The lowest price target for CI is $323.00 from at , which represents a 0.6% increase from the current price of $321.23.
What is the overall CI consensus from analysts for The Cigna Group?
The overall analyst consensus for CI is bullish. Out of 36 Wall Street analysts, 19 rate it as Buy, 6 as Hold, and 0 as Sell, with a median price target of $360.00.
How accurate are CI stock price projections?
Stock price projections, including those for The Cigna Group, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
